基因组胺受体在儿科AML中的表达和临床意义
Bi Zhou1,2, WenPeng Wang3, Pao Yu1
1Department of Pediatrics, Suzhou Hospital of Anhui Medical University, Suzhou, People's Republic of China.
Hematology (Amsterdam, Netherlands)
|February 7, 2025
概括
组胺受体H1 (HRH1) 在儿科急性髓性白血病 (AML) 中升高,并预测更好的无事件和无复发的生存率. 高HRH1表达表明风险较低,表明其作为儿科AML早期预后标志物的潜力.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 研究了儿科急性髓性白血病 (AML) 中组胺受体 (HRs) 的表达和临床意义.
- 专注于新诊断的儿科AML患者的骨髓微环境.
研究的目的:
- 评估儿科AML中组胺受体家族成员 (HRH1,HRH2,HRH3和HRH4) 的表达水平.
- 确定儿童AML患者HRs的临床意义和预后价值.
主要方法:
- 在化疗前,从140名儿科AML患者的骨髓RNA测序.
- 在不同风险类别中对HR表达的比较.
- ROC曲线分析,以评估HRs对患者结果的预测能力.
主要成果:
- 与正常对照组相比,儿科AML患者的HRH1表达显著更高.
- 高HRH1表达与明显更好的无事件存活率 (EFS) 和无复发存活率 (RFS) 相相关.
- 在低风险组中,HRH1的表达显著更高,这表明它作为早期预测者的作用.
结论:
- 组胺受体家族成员在儿科AML中具有不同的临床意义.
- HRH1被确定为儿科AML复发的有价值预测因素.
- HRH1可能作为儿童AML风险分层和生存结果的早期预后标志物.
相关概念视频
Allergic Reactions
Overview
Allergic Drug Reactions
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Allergic Reactions: Anaphylaxis
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...
Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...


